First-in-Class HCV Drug Licensed by Novartis
Novartis licenses Hepatitis C drug
Feb. 9, 2010
By Steve Goldstein
LONDON (MarketWatch) — Novartis /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 53.73, +0.02, +0.04%) /quotes/comstock/06p!novn (CH:NOVN 57.80, 0.00, 0.00%) said it has licensed Debio 025, or alisporivir, a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.
Continue reading this entire article:
Celebrating Valentine's Day: A Sweet Treat for Hepatitis C
Ten Tips to Relieve HCV-Related Itching